Nueclear Web Banner
Users Online: 483
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2014  |  Volume : 3  |  Issue : 1  |  Page : 66-70

Management of relapsed-refractory diffuse large B cell lymphoma


Institute of Haematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal, India

Correspondence Address:
Lalit S Raut
Institute of Haematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-330X.126531

Rights and Permissions

Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed by autologous stem cell transplantation is the standard of care for chemosensitive relapses in DLBCL. Various salvage regimens are available, but the quest for an optimal regimen continues. The addition of rituximab to the salvage regimen has improved the outcome of RR DLBCL. Several pertinent issues regarding the management of RR DLBCL are discussed in this short review.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2456    
    Printed36    
    Emailed1    
    PDF Downloaded814    
    Comments [Add]    
    Cited by others 11    

Recommend this journal